Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.7.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2017
Dec. 31, 2016
Current assets    
Cash $ 883 $ 14,305
Prepaid Expenses 7,619
Total current assets 8,502 14,305
Total Assets 8,502 14,305
Current liabilities    
Accounts payable 357,641 349,849
Accrued interest payable 323,509 302,834
Notes payable - current - related parties 602,350 627,022
Notes payable - current, net 163,574 163,574
Derivative liability 180,038
Stock subscription payable 38,401 28,081
Related party payables 1,041,434 1,111,754
Other payables 293,362 263,033
Total current liabilities 2,820,271 3,026,185
Total Liabilities 2,820,271 3,026,185
Stockholders' Deficit    
Preferred stock, $.00001 par value; 22,000,000 shares authorized, No shares issued or outstanding as of June 30, 2017 and December 31, 2016, respectively
Common stock, $.00001 par value; 800,000,000 shares authorized; 107,171,429 and 67,751,068 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively 1,072 677
Additional paid in capital 14,830,255 14,095,430
Accumulated deficit (17,597,176) (17,064,086)
Total Transbiotec, Inc. stockholders' deficit (2,765,849) (2,967,979)
Noncontrolling interest (45,920) (43,901)
Total Stockholders’ Deficit (2,811,769) (3,011,880)
Total Liabilities and Stockholders’ Deficit $ 8,502 $ 14,305
Series A Preferred Stock [Member]    
Stockholders' Deficit    
Series A Convertible Preferred stock, $.00001 par value; 3,000,000 shares authorized,No shares issued or outstanding as of June 30, 2017 and December 31, 2016, respectively